Latest Reimbursement News

Emyria Limited is on track to open its first Empax clinic in Victoria by Q2 2026, having secured key operational milestones including a trained clinical workforce and dual reimbursement pathways.

Worley has received the Full Notice to Proceed from Venture Global for Phase 2 of the CP2 LNG export project in Louisiana, marking a significant milestone following Venture Global’s Final Investment Decision.

EBR Systems marked a pivotal transition in 2025 with FDA approval of its WiSE CRT System and the initiation of U.S. commercial implants, generating $1.6 million in revenue. Despite this progress, the company reported a net loss of $48.8 million and completed a significant capital raise to support ongoing growth.

Corazon Mining Limited has secured rights to apply for exploration licences covering 537 km² in the Plutonic Marymia Greenstone Belt, following a withdrawal agreement with IGO Limited that includes access to proprietary historical data.

IperionX Limited has denied any undisclosed information following a sharp share price drop from $6.93 to $4.58, clarifying its accounting for U.S. government grants amid market volatility.

Acrux Limited has secured a $0.55 million advance on its FY26 R&D Tax Incentive, providing crucial funding to accelerate development of its Hormone Replacement Therapy following FDA regulatory confirmation.

Adherium Limited reports a strong uptick in Remote Patient Monitoring revenue and device activations, driven by new reimbursement codes and strategic partnerships, aiming for 10,000 RPM patients by year-end.

Rhythm Biosciences has achieved a significant regulatory milestone with NATA accreditation for its ColoSTAT® blood-based colorectal cancer test, enabling its commercial rollout in Australia and strengthening reimbursement prospects.

Control Bionics has secured a key regulatory milestone with its NeuroNode device now eligible for reimbursement under Germany’s statutory health insurance, paving the way for expanded European distribution.

Botanix Pharmaceuticals reports a surge in Sofdra sales driving revenue to $16.5 million, yet the company records a $33.2 million loss amid expanded marketing and operational costs. A $45 million capital raise aims to support growth and supply chain improvements.

PainChek Limited reported a half-year loss of AUD 4.7 million but achieved a major regulatory milestone with FDA clearance for its Adult App, unlocking significant US market opportunities. The company also completed a share consolidation and raised capital to support growth.

Lumos Diagnostics reported a 74% increase in its half-year loss to US$4.88 million, despite strong progress with its FebriDx diagnostic test and a landmark US distribution agreement. The company awaits a critical FDA decision that could unlock significant revenue growth.